March 25, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector got robbed again of share pricing value
March 24, 2022
RegMed Investors’ (RMi) closing bell: upside holding its own while riding the waves of a positive market
March 23, 2022
RegMed Investors’ (RMi) closing bell: after yesterday’s gains, there’s today’s pains – yet again
March 22, 2022
RegMed Investors’ (RMi) closing bell: adjusting expectation, the monkey bars versus the slide
March 21, 2022
RegMed Investors’ (RMi) closing bell: The sector got whacked as the electronics and algorithms ate through any upside
March 21, 2022
RegMed Investors’ (RMi) closing bell: sector highs respond to lessened resistance motivating sentiment
March 21, 2022
RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk
March 17, 2022
RegMed Investors’ (RMi) closing bell: Algorithmic tailwinds are pushing the cell and gene therapy sector upward
March 15, 2022
RegMed Investors’ (RMi) closing bell: it’s about time for the oversold cell and gene therapy sector logjam to come back to appreciation
March 14, 2022
RegMed Investors’ (RMi) closing bell: just when I thought sentiment would rebound and lift the cell and gene therapy sector
March 11, 2022
RegMed Investors’ (RMi) closing bell: escalated depreciation in the cell and gene therapy sector
March 10, 2022
RegMed Investors’ (RMi) closing bell: the algorithms beat me to the profit window
March 9, 2022
RegMed Investors’ (RMi) closing bell: a pocket of appreciation, how long will it last?
March 8, 2022
RegMed Investors’ (RMi) closing bell: news, earnings and oversold conditions drive sector’s risk slide
March 7, 2022
RegMed Investors’ (RMi) closing bell: the economic ramifications of disruption, selling into oversold conditions
March 4, 2022
RegMed Investors’ (RMi) closing bell: the advance/decline line pooped the stoop
March 3, 2022
RegMed Investors’ (RMi) closing bell: a worried sector, downtrodden by war anxieties
March 2, 2022
RegMed Investors’ (RMi) closing bell: a wild up and down open as cell and gene therapy sector closes positive
March 1, 2022
RegMed Investors’ (RMi) closing bell: the wall-of-worry wavers from sector’s risk-off to risk-on
February 28, 2022
RegMed Investors’ (RMi) closing bell: despite starting with a sell-off, the cell and gene therapy reaped a bare upside as the oversold lost and gained momentum
February 25, 2022
RegMed Investors’ (RMi) closing bell: share pricing risk decline from a headline drive market to close sector positive
February 24, 2022
RegMed Investors’ (RMi) closing bell: a lot of buys on first day of a disclosed Ukraine attack
February 23, 2022
RegMed Investors’ (RMi) closing bell: what happened, blood from the past and on-going sessions drowns sentiment
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.